LeMaitre Vascular (NASDAQ:LMAT) Price Target Raised to $105.00

LeMaitre Vascular (NASDAQ:LMAT) had its price objective upped by Barrington Research from $95.00 to $105.00 in a research note released on Thursday morning,Benzinga reports. The firm currently has an outperform rating on the medical instruments supplier’s stock.

A number of other equities research analysts also recently commented on LMAT. Cantor Fitzgerald restated a “neutral” rating and issued a $95.00 price objective on shares of LeMaitre Vascular in a research report on Monday, November 10th. Zacks Research downgraded LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a research note on Thursday, January 1st. Wells Fargo & Company lifted their price target on LeMaitre Vascular from $87.00 to $94.00 and gave the company an “equal weight” rating in a research note on Thursday. Roth Mkm reaffirmed a “buy” rating and set a $117.00 price objective (up from $108.00) on shares of LeMaitre Vascular in a report on Thursday. Finally, Weiss Ratings cut LeMaitre Vascular from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday. Three equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $105.80.

LeMaitre Vascular Stock Performance

NASDAQ:LMAT opened at $108.18 on Thursday. The firm’s fifty day moving average price is $87.02 and its 200 day moving average price is $88.36. LeMaitre Vascular has a 1-year low of $71.42 and a 1-year high of $115.33. The company has a debt-to-equity ratio of 0.44, a current ratio of 13.58 and a quick ratio of 11.45. The firm has a market cap of $2.45 billion, a price-to-earnings ratio of 43.10, a price-to-earnings-growth ratio of 2.19 and a beta of 0.72.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings data on Wednesday, February 25th. The medical instruments supplier reported $0.68 EPS for the quarter, topping analysts’ consensus estimates of $0.67 by $0.01. LeMaitre Vascular had a net margin of 23.13% and a return on equity of 15.02%. The company had revenue of $64.45 million during the quarter, compared to the consensus estimate of $62.98 million. During the same quarter in the prior year, the firm earned $0.49 EPS. LeMaitre Vascular’s quarterly revenue was up 15.7% on a year-over-year basis. LeMaitre Vascular has set its FY 2026 guidance at 2.810-3.010 EPS and its Q1 2026 guidance at 0.640-0.690 EPS. On average, sell-side analysts expect that LeMaitre Vascular will post 1.94 EPS for the current year.

LeMaitre Vascular Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 26th. Investors of record on Thursday, March 12th will be issued a dividend of $0.25 per share. This is a boost from LeMaitre Vascular’s previous quarterly dividend of $0.20. This represents a $1.00 annualized dividend and a yield of 0.9%. The ex-dividend date of this dividend is Thursday, March 12th. LeMaitre Vascular’s payout ratio is presently 31.87%.

Institutional Investors Weigh In On LeMaitre Vascular

A number of large investors have recently added to or reduced their stakes in the business. M&T Bank Corp increased its holdings in LeMaitre Vascular by 2,240.5% during the 4th quarter. M&T Bank Corp now owns 398,069 shares of the medical instruments supplier’s stock valued at $32,283,000 after acquiring an additional 381,061 shares in the last quarter. Goldman Sachs Group Inc. grew its position in shares of LeMaitre Vascular by 144.4% in the fourth quarter. Goldman Sachs Group Inc. now owns 391,254 shares of the medical instruments supplier’s stock valued at $31,731,000 after purchasing an additional 231,157 shares during the last quarter. First Trust Advisors LP increased its stake in shares of LeMaitre Vascular by 35.4% during the 3rd quarter. First Trust Advisors LP now owns 828,947 shares of the medical instruments supplier’s stock worth $72,541,000 after purchasing an additional 216,919 shares in the last quarter. Millennium Management LLC raised its position in shares of LeMaitre Vascular by 119.8% during the 1st quarter. Millennium Management LLC now owns 211,222 shares of the medical instruments supplier’s stock worth $17,722,000 after purchasing an additional 115,141 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in LeMaitre Vascular by 20.1% in the 4th quarter. Geode Capital Management LLC now owns 633,089 shares of the medical instruments supplier’s stock valued at $51,351,000 after buying an additional 105,921 shares in the last quarter. 84.64% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about LeMaitre Vascular

Here are the key news stories impacting LeMaitre Vascular this week:

• Positive Sentiment: Q4 results beat and above‑consensus guidance: LeMaitre reported $0.68 EPS vs. $0.67 consensus and revenue of $64.45M (vs. $62.98M est.); management raised Q1 and FY2026 EPS and revenue guidance, signaling continued top‑line momentum. Press Release
• Positive Sentiment: Dividend increase: Company raised the quarterly dividend 25% to $0.25/share (ex‑dividend March 12), returning cash to shareholders and supporting income‑oriented demand.
• Positive Sentiment: Analyst bullishness: Multiple firms raised ratings/targets — Citizens JMP to $118 (market outperform) and Roth MKM reaffirmed Buy and raised target to $117 — these are constructive for sentiment. Analyst Note
• Neutral Sentiment: Investor outreach: Management will participate in five investor conferences in March, increasing visibility and allowing direct Q&A with investors. Conference Notice
• Neutral Sentiment: Earnings call coverage and transcripts are available for deeper color on drivers (procedure volumes, product mix, backlog) for investors doing fundamental diligence. Earnings Transcript
• Negative Sentiment: Mixed analyst targets; some firms still imply downside: Wells Fargo raised its target but keeps an “equal weight” rating with a $94 target (below current price), and a few targets remain lower than the stock’s recent level — this can trigger profit‑taking or short‑term selling. Analyst Notes

About LeMaitre Vascular

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.